Toshali Pandey

Featured in: Favicon

Articles

Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience - Bone Marrow Transplantation

1 month ago | nature.com | Eric Siegel |Carolina Schinke |Frits van Rhee |Toshali Pandey

B-cell maturation antigen (BCMA) chimeric antigen receptor T (CAR T)-cell therapy has significantly advanced the treatment of relapsed/refractory (R/R) multiple myeloma (MM) [1]. In the phase II KarMMa trial, idecabtagene vicleucel (ide-cel) achieved a median progression-free survival (PFS) of 8.8 months and overall survival (OS) of 19.4 months in triple-class-exposed RRMM patients [2].

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.